Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Kallmann, Boris A.
44  Ergebnisse:
Personensuche X
?
1

REBISTART: Adherence of Patients with Multiple Sclerosis to..:

Schwab, Matthias ; Chan, Andrew ; Eser, Anna-Katharina...
Neurology and Therapy.  13 (2024)  3 - p. 641-653 , 2024
Link: https://doi.org/10.1007/..
 
?
2

Ambulante spezialfachärztliche Versorgung (ASV) für die mul..:

Mäurer, Mathias ; Meier, Uwe ; Wattjes, Mike P....
DGNeurologie.  6 (2023)  6 - p. 481-492 , 2023
Link: https://doi.org/10.1007/..
 
?
3

Long-term management of multiple sclerosis patients treated..:

Meuth, Sven G ; Bayas, Antonios ; Kallmann, Boris...
Expert Opinion on Pharmacotherapy.  23 (2022)  13 - p. 1503-1510 , 2022
Link: https://doi.org/10.1080/..
 
?
4

Multiple sclerosis therapy consensus group (MSTCG): answers..:

Wiendl, Heinz ; Gold, Ralf ; Zipp, Frauke...
Neurological Research and Practice.  3 (2021)  1 - p. , 2021
Link: https://doi.org/10.1186/..
 
?
5

Multiple Sklerose Therapie Konsensus Gruppe (MSTKG): Positi..:

Wiendl, Heinz ; Gold, Ralf ; Berger, Thomas...
Der Nervenarzt.  92 (2021)  8 - p. 773-801 , 2021
Link: https://doi.org/10.1007/..
 
?
6

Teriflunomide in relapsing-remitting multiple sclerosis: ou..:

Kallmann, Boris A. ; Ries, Stefan ; Kullmann, Jennifer S....
Therapeutic Advances in Neurological Disorders.  14 (2021)  - p. 175628642110055 , 2021
Link: https://doi.org/10.1177/..
 
?
7

Multiple Sclerosis Therapy Consensus Group (MSTCG): positio..:

Wiendl, Heinz ; Gold, Ralf ; Berger, Thomas...
Therapeutic Advances in Neurological Disorders.  14 (2021)  - p. 175628642110396 , 2021
Link: https://doi.org/10.1177/..
 
?
8

Clinical outcomes and treatment satisfaction in patients sw..:

Freedman, Mark S. ; Kallmann, Boris A. ; Meca-Lallana, Jose E....
Neurology.  94 (2020)  15_supplement - p. , 2020
Link: https://doi.org/10.1212/..
 
?
9

Real-life outcomes of teriflunomide treatment in patients w..:

Kallmann, Boris A. ; Tiel-Wilck, Klaus ; Kullmann, Jennifer S...
Therapeutic Advances in Neurological Disorders.  12 (2019)  - p. 175628641983507 , 2019
Link: https://doi.org/10.1177/..
 
?
10

Treatment Optimization Using a Multidimensional Decision Mo..:

Stangel, Martin ; Kallmann, Boris ; Schruefer, Ruth.
Neurology.  90 (2018)  15_supplement - p. , 2018
Link: https://doi.org/10.1212/..
 
?
11

An epidemiological study on the course of disease and thera..:

Schmidt, Stephan ; Koehler, Jürgen ; Winterstein, Christine..
Therapeutic Advances in Neurological Disorders.  11 (2018)  - p. 175628561774980 , 2018
Link: https://doi.org/10.1177/..
 
?
12

Alemtuzumab as rescue therapy in a cohort of 50 relapsing–r..:

Huhn, Konstantin ; Bayas, Antonios ; Doerck, Sebastian...
Journal of Neurology.  265 (2018)  7 - p. 1521-1527 , 2018
Link: https://doi.org/10.1007/..
 
?
13

Fatal Autoimmune Hemolytic Anemia Associated with Alemtuzum..:

Rieckmann, Peter ; Lenz, Arne ; Hoffmann, Markus...
Neurology.  86 (2016)  16_supplement - p. , 2016
Link: https://doi.org/10.1212/..
 
?
14

Bedeutung regionaler Netzwerke bei der Versorgung von MS-Pa..:

Kallmann, Boris ; Mäurer, Mathias ; Linker, Ralf.
DNP - Der Neurologe und Psychiater.  15 (2014)  12 - p. 64-67 , 2014
Link: https://doi.org/10.1007/..
 
?
15

Adherence To, And Effectiveness Of, Treatment With Subcutan..:

Bayas, Antonios ; Ouallet, Jean-Christophe ; Kallmann, Boris...
Neurology.  82 (2014)  10_supplement - p. , 2014
Link: https://doi.org/10.1212/..
 
1-15